Scalable system-wide cyp2c19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptions [editorial]
Editorial Article
Overview
Link to Article
10.1161/circgen.125.005363
authors
Telis, N.
Stoller, D. A.
Chapman, C. N.
Chahal, C. A. A.
Judge, D. P.
Olson, D. A.
Grzymski, J. J.
Hajek, C.
Kruisselbrink, T.
Washington, N. L.
Cirulli, E. T.
publication date
2026
published in
Circulation. Genomic and precision medicine
Journal
Research
keywords
Adverse Effects
Cardiovascular Diseases
Drugs and Drug Therapy
Genetics
Heart Diseases
Additional Document Info
volume
19
issue
3
